Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android. Learn more here!

Rare genetic disorder characterized by complete or partial lack of the enzyme ornithine transcarbamylase (OTC). Lack of the enzyme results in excessive hyperammonemia, which is known as a neurotoxin. Clinically, patients present vomiting, refusal to eat, progressive lethargy, and coma.

Ornithine Transcarbamylase Deficiency.

The urea cycle disorders are a group of rare disorders that affect the urea cycle, a series of biochemical processes in which nitrogen is converted into urea and removed from the body through the urine. Nitrogen is a waste product of protein metabolism. Failure to break down nitrogen results in the abnormal accumulation of nitrogen, in the form of ammonia, in the blood.

Approximately 1:80,000 live births. Estimated prevalence for disorders of urea cycle is approximately 1:30,000 population.

Partially dominant X-linked (Xp21.1). The phenotype of heterozygote females cannot be predicted because of random inactivation of the X chromosome. Some female carriers present clinical symptoms a few weeks after delivery, at the time of uterine involution.

Ornithine carbamoyltransferase is one of six enzymes that play a role in the breakdown and removal of nitrogen in the body, a process known as the urea cycle. The entire urea cycle resides exclusively in periportal hepatocytes. It is an essential pathway for waste nitrogen excretion. It is involved in a cascade of six enzymatic transformations converting toxic ammonia to nontoxic water-soluble urea.

Elevated blood NH4 level in a lethargic or comatose patient; liver biopsy; increased urinary orotic acid levels.

Neonatal Presentation: Starts within the first 4 days of life: refusal to feed, irritability, persistent vomiting, mild respiratory alkalosis, followed rapidly by neurologic signs with coma, convulsions, hypotonia.

Late-Onset Presentation: Long history of chronic hepatogastric symptoms such as recurrent episodes of vomiting, failure to thrive, and hepatomegaly. Others present a neurologic picture of chronic encephalopathy; behavioral disorders such as agitation, delirium, and irritability; or Reye-like syndrome following sodium valproate therapy for seizures. Some patients spontaneously avoid protein-rich food and remain relatively asymptomatic. Death may occur during a metabolic crisis precipitated by infection, surgery, increased catabolism, or a protein-rich diet.

In case of seizures, sodium valproate should not be used because it may precipitate acute metabolic decompensation. Liver transplantation is curative.

Basic treatment is a low-protein diet carefully adapted to the child's needs and metabolic tolerance and administration of ammonia-scavenging drugs (Na-benzoate, Na-phenylbutyrate, l-arginine) three to four times per day. Their administration should be linked to meals to maximize their effect.

In case of hyperammonemia:

  • Stop protein intake and restrict fluid volume if there is any concern about cerebral edema. Provide a high-energy intake orally or IV (glucose 10-20%).
  • Use alternative pathways for nitrogen elimination: give Na-benzoate up to 500 mg/kg/day, Na-phenylbutyrate up to 600 mg/kg/day, and l-arginine 300 mg/kg/day orally or IV. Because these drugs lead to ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.